Joseph Sassine is an Infectious Disease physician affiliated with University of Oklahoma Medical Center. OpenAlex indexes 69 publications with 481 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Stanton L Young Blvd Ste 7300
Oklahoma City, OK 731045018
Telephone
405-271-6122Provider last certified this registry record 17 Aug 2021.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- Paratek Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
89.6%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor16.3%Triumeq66%Descovy34%Part D<11 patientsMacrolide Antimicrobial13.9%Azithromycin100%Part D<11 patients+ 9 more classes in this area
Cardiovascular
5.6%Statin5.6%Atorvastatin Calcium100%Part D<11 patientsSensory organs
4.8%Fluoroquinolone Antibacterial4.8%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy
Clinical Infectious Diseases
2026 - Disseminated adenovirus infection following CAR T-cell therapy: Early-onset presentation in a patient with relapsed refractory mantle cell lymphoma
Clinical Hematology International
2026 - 85. Risk Factors and Outcomes of Resistant CMV Infections in Hematopoietic Cell Transplant Recipients: a 7-Year Review
Open Forum Infectious Diseases
2026 - Comparing Infectious Complications Following CD19 Chimeric Antigen Receptor T cell Therapy and Autologous Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies
Biology of Blood and Marrow Transplantation
2026 - P-1851. OPAT Safety Outcomes with Cefepime vs Piperacillin-Tazobactam
Open Forum Infectious Diseases
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Shinobu Itagaki, MD
University of Oklahoma Medical Center
Nana Toyoda, MD
University of Oklahoma Medical Center
Angelia Kirkpatrick, MD
University of Oklahoma Medical Center
Niyaz Gosmanov, MD
University of Oklahoma Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”